

Polymyositis Market - A Global and Regional Analysis: Focus on Treatment Type, Route of Administration, Country, and Region - Analysis and Forecast, 2026-2036

<https://marketpublishers.com/r/PC278D50797EEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: PC278D50797EEN

Abstracts

Polymyositis is a rare, inflammatory muscle disease that primarily affects the skeletal muscles, causing weakness and inflammation. It is classified as one of the idiopathic inflammatory myopathies (IIM), a group of diseases characterized by muscle inflammation and weakness without a known cause. Polymyositis typically affects the muscles closest to the body's trunk, such as those in the hips, thighs, shoulders, and upper arms, leading to difficulty with movements like standing up, climbing stairs, or lifting objects.

The polymyositis market is experiencing substantial growth due to an increasing global prevalence of the disease, particularly among older adults. Polymyositis is an autoimmune disorder that leads to inflammation and weakness in skeletal muscles, making early diagnosis and effective treatment crucial for patient outcomes. The market is primarily driven by advancements in therapeutics, including the shift towards biologics and immunosuppressants, offering more targeted treatment options compared to traditional corticosteroids. Rising disease awareness, particularly among healthcare professionals and patients, is also driving demand for effective therapies. The need for personalized treatment options is creating opportunities for the development of drugs tailored to the specific genetic and clinical biomarker profiles of patients, which could significantly improve therapeutic efficacy.

Additionally, there is an increasing focus on emerging markets like Asia-Pacific and Latin America, where improving healthcare infrastructure and growing awareness of autoimmune disorders and drug delivery are expected to fuel market expansion. The

Integration of telemedicine platforms also represents a key opportunity, allowing for improved patient monitoring, accessibility to care, and better treatment adherence, especially in remote areas. Regionally, North America holds the largest share of the market, attributed to its advanced healthcare infrastructure, substantial research investments, and higher disease awareness, while Europe also plays a critical role due to strong regulatory frameworks and ongoing collaborations in drug development. The Asia-Pacific region, with its large patient population and growing healthcare investments, is expected to show the fastest growth. The competitive landscape is dominated by major players such as Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer, all of which are focusing on expanding their product pipelines through research and development to introduce innovative therapies. These companies are actively working to address the unmet needs in the polymyositis market, including the development of treatments that offer better safety profiles, improved efficacy, and convenient administration routes. As the market continues to evolve, stakeholders who invest in novel drug development, regional market penetration, and digital health solutions will be well-positioned to capitalize on the growing demand for polymyositis treatments.

Market Segmentation:

Segmentation 1: by Treatment Type

Corticosteroids

Immunosuppressants

Biologics

Supportive therapies

Segmentation 2: by ROA

Oral

Intravenous

Intramuscular

Segmentation 3: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary

Scope of Study

1. GLOBAL POLYMYOSITIS MARKET: INDUSTRY OUTLOOK

1.1 Market Overview and Ecosystem

1.2 Polymyositis Disease Profile

1.3 Treatment Landscape

1.4 Clinical Presentation and Diagnosis

1.5 Epidemiological Analysis of Polymyositis Market in U.S., EU5 and APAC Countries

1.5.1 Regional Disease Incidence and Prevalence

1.5.2 Distribution by Demographic Factors

1.5.3 Geographical Distribution and Hotspots

1.5.4 Age Distribution by Region

1.6 Market Trends

1.7 Clinical Trial Landscape

1.8 Regulatory Landscape Analysis

1.8.1 Legal Requirement and Framework in U.S.

1.8.2 Legal Requirement and Framework in E.U.

1.8.3 Legal Requirement and Framework in Asia-Pacific

1.8.4 Legal Requirement and Framework in Rest-of-the-World

1.9 Market Dynamics

1.9.1 Impact Analysis

1.9.2 Market Drivers

1.9.3 Market Restraints

1.9.4 Market Opportunities

2. GLOBAL POLYMYOSITIS MARKET, (BY TREATMENT TYPE), \$MILLION, 2025-2036

2.1 Overview

2.2 Corticosteroids

2.3 Immunosuppressants

2.4 Biologics

2.5 Supportive Therapies.

3. GLOBAL POLYMYOSITIS MARKET, (BY ROUTE OF ADMINISTRATION),

\$MILLION, 2025-2036

- 3.1 Overview
- 3.2 Oral
- 3.3 Intravenous
- 3.4 Intramuscular

4. GLOBAL POLYMYOSITIS MARKET, (BY REGION), \$MILLION, 2025-2036

- 4.1 North America
 - 4.1.1 Key Findings
 - 4.1.2 Market Dynamics
 - 4.1.3 Market Sizing and Forecast
 - 4.1.3.1 North America Polymyositis Market (by Country)
 - 4.1.3.1.1 U.S.
 - 4.1.3.1.2 Canada
- 4.2 Europe
 - 4.2.1 Key Findings
 - 4.2.2 Market Dynamics
 - 4.2.3 Market Sizing and Forecast
 - 4.2.3.1 Europe Polymyositis Market (by Country)
 - 4.2.3.1.1 Germany
 - 4.2.3.1.2 France
 - 4.2.3.1.3 Italy
 - 4.2.3.1.4 Spain
 - 4.2.3.1.5 U.K.
 - 4.2.3.1.6 Rest-of-Europe
- 4.3 Asia-Pacific
 - 4.3.1 Key Findings
 - 4.3.2 Market Dynamics
 - 4.3.3 Market Sizing and Forecast
 - 4.3.3.1 Asia-Pacific Polymyositis Market (by Country)
 - 4.3.3.1.1 Japan
 - 4.3.3.1.2 China
 - 4.3.3.1.3 India
 - 4.3.3.1.4 Australia
 - 4.3.3.1.5 South Korea
 - 4.3.3.1.6 Rest-of-Asia-Pacific
- 4.4 Rest-of-the-World

- 4.4.1 Key Findings
- 4.4.2 Market Dynamics
- 4.4.3 Market Sizing and Forecast

5. GLOBAL POLYMYOSITIS MARKET: COMPETITIVE BENCHMARKING AND COMPANY PROFILES

- 5.1 Competitive Benchmarking
- 5.2 Competitive Landscape
 - 5.2.1 Key Strategies and Developments by Company
 - 5.2.1.1 Funding Activities
 - 5.2.1.2 Mergers and Acquisitions
 - 5.2.1.3 Regulatory Approvals
 - 5.2.1.4 Partnerships, Collaborations, and Business Expansions
 - 5.2.2 Key Developments Analysis
- 5.3 Company Profiles
 - 5.3.1 Teva Pharmaceuticals
 - 5.3.1.1 Company Overview
 - 5.3.1.2 Product Portfolio
 - 5.3.1.3 Target Customers/End Users
 - 5.3.1.4 Key Personnel
 - 5.3.1.5 Analyst View
 - 5.3.2 Gilead Sciences
 - 5.3.2.1 Company Overview
 - 5.3.2.2 Product Portfolio
 - 5.3.2.3 Target Customers/End Users
 - 5.3.2.4 Key Personnel
 - 5.3.2.5 Analyst View
 - 5.3.3 Eli Lilly and Company
 - 5.3.3.1 Company Overview
 - 5.3.3.2 Product Portfolio
 - 5.3.3.3 Target Customers/End Users
 - 5.3.3.4 Key Personnel
 - 5.3.3.5 Analyst View
 - 5.3.4 Celgene
 - 5.3.4.1 Company Overview
 - 5.3.4.2 Product Portfolio
 - 5.3.4.3 Target Customers/End Users
 - 5.3.4.4 Key Personnel

- 5.3.4.5 Analyst View
- 5.3.5 AsteraZeneca
 - 5.3.5.1 Company Overview
 - 5.3.5.2 Product Portfolio
 - 5.3.5.3 Target Customers/End Users
 - 5.3.5.4 Key Personnel
 - 5.3.5.5 Analyst View
- 5.3.6 Amgen Inc.
 - 5.3.6.1 Company Overview
 - 5.3.6.2 Product Portfolio
 - 5.3.6.3 Target Customers/End Users
 - 5.3.6.4 Key Personnel
 - 5.3.6.5 Analyst View
- 5.3.7 Bristol-Meyer Squibb
 - 5.3.7.1 Company Overview
 - 5.3.7.2 Product Portfolio
 - 5.3.7.3 Target Customers/End Users
 - 5.3.7.4 Key Personnel
 - 5.3.7.5 Analyst View
- 5.3.8 AbbVie
 - 5.3.8.1 Company Overview
 - 5.3.8.2 Product Portfolio
 - 5.3.8.3 Target Customers/End Users
 - 5.3.8.4 Key Personnel
 - 5.3.8.5 Analyst View
- 5.3.9 Pfizer, Inc.
 - 5.3.9.1 Company Overview
 - 5.3.9.2 Product Portfolio
 - 5.3.9.3 Target Customers/End Users
 - 5.3.9.4 Key Personnel
 - 5.3.9.5 Analyst View
- 5.3.10 Boehringer Ingelheim.
 - 5.3.10.1 Company Overview
 - 5.3.10.2 Product Portfolio
 - 5.3.10.3 Target Customers/End Users
 - 5.3.10.4 Key Personnel
 - 5.3.10.5 Analyst View

6. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Polymyositis Market (by Scenario), \$Million, 2025, 2030, and 2036

Figure: Global Polymyositis Market, 2025 and 2036

Figure: Global Polymyositis Market Key Trends, Impact Analysis

Figure: North America Polymyositis Market, \$Million, 2025-2036

Figure: Europe Polymyositis Market, \$Million, 2025-2036

Figure: Asia-Pacific Polymyositis Market, \$Million, 2025-2036

Figure: Rest-of-the-World Polymyositis Market, \$Million, 2025-2036

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Polymyositis Market (by Treatment Type), \$Million, 2025-2036

Table: Global Polymyositis Market (by Route of Administration), \$Million, 2025-2036

Table: Global Polymyositis Market (by Region), \$Million, 2025-2036

I would like to order

Product name: Polymyositis Market - A Global and Regional Analysis: Focus on Treatment Type, Route of Administration, Country, and Region - Analysis and Forecast, 2026-2036

Product link: <https://marketpublishers.com/r/PC278D50797EEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC278D50797EEN.html>